Physician profile
Michael H Albert
NPI 1679562094
$3,014.15
in general payments reported to CMS, 2019-2025
33 companies · $556 in 2025
The $556 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $218 · 2021: $526 · 2022: $347 · 2023: $344 · 2024: $749 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $306.13 | 2023-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $304.73 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $239.42 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $223.08 | 2022-2025 | Austedo Xr, Austedo |
| Ucb, INC. | $189.97 | 2024 | Nayzilam |
| Bayer Healthcare Pharmaceuticals INC. | $168.77 | 2021-2025 | |
| Lilly USA, LLC | $140.00 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $129.00 | 2020-2023 | Myrbetriq |
| Novo Nordisk INC | $118.95 | 2020-2025 | Ozempic, Rybelsus |
| Neurocrine Biosciences, INC. | $109.06 | 2022-2025 | Ingrezza |
| Allergan, INC. | $106.97 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $103.01 | 2019-2022 | |
| Smith+Nephew, INC. | $99.52 | 2024 | Collagenase Santyl |
| Lundbeck LLC | $97.99 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $81.95 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $78.55 | 2023-2024 | Gemtesa |
| Pfizer INC. | $77.25 | 2021-2025 | |
| Eisai INC. | $68.03 | 2020-2021 | |
| Exact Sciences Corporation | $53.56 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $49.50 | 2020-2024 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.18 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.21 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.15 | 2022 | |
| Philips North America LLC | $25.60 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.65 | 2024 | |
| Abbott Laboratories | $17.88 | 2022 | |
| Inari Medical, INC. | $17.80 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ironshore Pharmaceuticals INC. | $16.84 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.50 | 2023 | Quviviq |
| Dexcom, INC. | $16.37 | 2021 | |
| Axsome Therapeutics, INC. | $16.27 | 2024 | Auvelity |
| Sun Pharmaceutical Industries INC. | $16.21 | 2020 | |
| Scilex Pharmaceuticals INC. | $16.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.